Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 241.83 -1.27 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $243.10 | 52 Week High | $333.65 | |||
| Open | $242.02 | 52 Week Low | $223.02 | |||
| Day High | $243.32 | P/E | 30.96 | |||
| Day Low | $240.13 | EPS | $7.81 | |||
| Volume | 381,830 | |||||
| (NASDAQ: STOK) | Delayed: 25.48 -1.13 (4.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.61 | 52 Week High | $ | |||
| Open | $26.83 | 52 Week Low | $ | |||
| Day High | $27.22 | P/E | N/A | |||
| Day Low | $25.31 | EPS | $ | |||
| Volume | 1,100,473 | |||||
